The fully linked HTML version of this article has now been published.
JCS ePress
online publication date 22 Feb 2005
doi: 10.1242/jcs.01708
Research Article
3
1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: a novel mechanism of integrin-mediated MMP gene expression
Vandana Iyer,
Kevin Pumiglia,
and
C. Michael DiPersio*
* Author for correspondence (e-mail: dipersm{at}mail.amc.edu)
Matrix metalloproteinases facilitate cell migration and tumor invasion through their ability to proteolyse the extracellular matrix. The laminin-binding integrin
3
1 is expressed at high levels in squamous cell carcinomas and in normal keratinocytes during cutaneous wound healing. We showed previously that
3
1 is required for MMP-9/gelatinase B secretion in immortalized mouse keratinocytes (MK cells) and that this regulation was acquired as part of the immortalized phenotype, suggesting a possible role for
3
1 during malignant conversion. In the current study, we identify a novel mechanism whereby
3
1 regulates the induction of MMP-9 expression that occurs in response to activation of a MAPK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway. Inhibition of MEK/ERK signaling in wild-type MK cells with a pharmacological inhibitor, U0126, showed that ERK activation was necessary for high levels of endogenous MMP-9 gene expression and activity of a transfected MMP-9 promoter. Furthermore, activation of MEK/ERK signaling in these cells with an oncogenic mutant of Ras, RasV12, increased both endogenous MMP-9 gene expression and MMP-9 promoter activity. Experiments with
3
1-deficient MK cells revealed that
3
1 was required for both baseline levels and RasV12-induced levels of MMP-9 mRNA expression. However,
3
1 was not required for RasV12-mediated activation of ERK or for ERK-dependent MMP-9 promoter activity. Direct comparison of mRNA turnover in the wild type and
3-null MK cells identified a requirement for
3
1 in stabilization of MMP-9 mRNA transcripts. These results identify a novel function for integrins in promoting mRNA stability as a mechanism to potentiate MAPK-mediated gene expression. They also suggest a role for
3
1 in maintaining high levels of MMP-9 mRNA expression in response to oncogenic activation of MEK/ERK signaling pathways.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Mitchell, C. Szekeres, V. Milano, K. B. Svenson, M. Nilsen-Hamilton, J. A. Kreidberg, and C. M. DiPersio
{alpha}3{beta}1 integrin in epidermis promotes wound angiogenesis and keratinocyte-to-endothelial-cell crosstalk through the induction of MRP3
J. Cell Sci.,
June 1, 2009;
122(11):
1778 - 1787.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Takagi, S. Simizu, and H. Osada
RECK Negatively Regulates Matrix Metalloproteinase-9 Transcription
Cancer Res.,
February 15, 2009;
69(4):
1502 - 1508.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Lamar, K. M. Pumiglia, and C. M. DiPersio
An Immortalization-Dependent Switch in Integrin Function Up-regulates MMP-9 to Enhance Tumor Cell Invasion
Cancer Res.,
September 15, 2008;
68(18):
7371 - 7379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. R. Nair, J. Solway, and D. D. Boyd
Expression Cloning Identifies Transgelin (SM22) as a Novel Repressor of 92-kDa Type IV Collagenase (MMP-9) Expression
J. Biol. Chem.,
September 8, 2006;
281(36):
26424 - 26436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J R Puddefoot, U K I Udeozo, S Barker, and G P Vinson
The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion.
Endocr. Relat. Cancer,
September 1, 2006;
13(3):
895 - 903.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Zhang, K. Furukawa, H.-H. Chen, T. Sakakibara, T. Urano, and K. Furukawa
Metastatic Potential of Mouse Lewis Lung Cancer Cells Is Regulated via Ganglioside GM1 by Modulating the Matrix Metalloprotease-9 Localization in Lipid Rafts
J. Biol. Chem.,
June 30, 2006;
281(26):
18145 - 18155.
[Abstract]
[Full Text]
[PDF]
|
 |
|
© The Company of Biologists Ltd 2005